Top 50 Ai For Drug Discovery in LATAM

Nintx develops next-generation pharmaceutical and nutraceutical therapies by translating complex intra- and interspecies biological interactions into novel treatments. The company leverages proprietary omics and data analytics technologies to discover natural product ingredients that modulate human biological targets and the gut microbiome. This platform focuses on creating multi-target solutions for multifactorial diseases linked to human biology and microbial crosstalk.

resistanceBio develops oncology drugs that focus on understanding and preventing drug resistance by mimicking the long-term evolution of cancer in a controlled environment. Their platform enables the identification of resistance pathways and the development of longer-lasting therapies, addressing the critical issue of treatment-resistant cancer that contributes to 90% of cancer mortality.

Onc.ai develops AI models leveraging oncology real-world data, including imaging, EMR, and genomics, to enhance precision oncology. The company's deep learning imaging AI aims to bring clarity to cancer treatment decision-making for medical oncologists. Initial products focus on predicting clinical outcomes in metastatic lung cancer to support pharmaceutical clinical development.

The startup develops personalized pharmaceutical technology that tailors medication regimens based on individual patient profiles, enhancing therapeutic efficacy and minimizing adverse effects. By utilizing advanced data analytics and pharmacogenomics, the company aims to improve patient outcomes and overall quality of life.

The startup specializes in identifying bioactive ribonucleic acid (RNA) from natural sources using machine learning and bioinformatics techniques. This enables researchers to enhance human health and resilience in response to environmental stressors through the application of RNA technologies.

Elytron utilizes biotechnology and artificial intelligence to analyze vast collections of microorganisms and their derivatives, predicting their efficacy for crop protection and nutrition. This approach accelerates the development of biopesticides, addressing the need for sustainable agricultural solutions that reduce reliance on chemical pesticides.

The startup is a biopharmaceutical company focused on developing novel therapeutics specifically targeting chronic gastrointestinal conditions through advanced drug formulation techniques. By addressing the unmet medical needs in this area, the company aims to improve patient outcomes and quality of life for those suffering from these persistent disorders.

The startup develops inhaled therapeutics that restore ion balance in the lungs of cystic fibrosis patients, improving lung function and overall health-related quality of life. Their approach also has potential applications in treating fungal infections, providing a new therapeutic avenue for affected individuals.

OmnigenicsAI is an AI-driven genomics company that provides secure, precise biological data to empower individuals in managing their health through personalized genomic insights. Their services include specialized genetic testing and telemedicine consultations, enabling proactive health management and informed healthcare decisions across all life stages.

TwoStep Therapeutics develops novel modalities to enhance the efficacy and expand the applicability of targeted cancer therapies. The company focuses on engineering drug conjugates designed for improved systemic delivery and tumor penetration. This approach aims to increase therapeutic windows for precision oncology treatments.

The startup develops laboratory-based diagnostic tests utilizing artificial intelligence, algorithms, and epigenomic profiling to detect all major subtypes of breast cancer from stage 1 to 4. With a sensitivity and specificity of 98.5%, their tests enable early and accurate cancer diagnosis, improving treatment outcomes for patients.

AntagomiR develops anti-miR oligonucleotides targeting upregulated microRNAs in myotonic dystrophy patients, addressing the underlying toxic DMPK and insufficient MBNL levels. Their fatty acid-conjugated delivery system enables effective treatment with a significantly reduced active dose directly to muscle tissue.

Exo develops handheld ultrasound devices integrated with artificial intelligence for imaging and therapeutic applications in medical settings. These devices enhance diagnostic accuracy and treatment efficiency, addressing the need for portable and user-friendly imaging solutions in healthcare.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

Neurolinx provides a semantic AI search and recommendation system that enhances data interaction through contextual understanding and personalized suggestions. This technology improves product discovery and operational efficiency for businesses by delivering precise search results and tailored recommendations, addressing the challenges of longtail search and user engagement.

The startup develops a generative artificial intelligence infrastructure that utilizes agent-based model-agnostic technology for evaluating and monitoring healthcare applications. Its software enables healthcare institutions to enhance operational efficiency and improve clinical outcomes by providing proprietary evaluation techniques and end-to-end lifecycle management.

Single Helix Genomics has developed an automated, portable device that delivers therapeutics on demand, utilizing advanced genomic technologies for precise treatment applications. This device addresses the need for immediate and personalized therapeutic solutions in various medical settings, enhancing patient care and treatment efficiency.

Embryoxite develops an AI-powered platform that analyzes embryo metabolomic data, genetic profiles, and morphokinetic imaging to assess implantation potential in pre-implantation embryos. This technology addresses the high failure rate of embryo implantation in IVF procedures by providing objective, data-driven insights that enhance selection accuracy and improve pregnancy outcomes.

The startup develops an AI-driven health tech software that enhances patient-clinic interactions through personalized and secure communication. This solution improves patient engagement and adherence to treatment, leading to better health outcomes in healthcare settings.

Vitalyze is a pharmaceutical rebate aggregator that utilizes a proprietary ingestion algorithm to collect and analyze drug administration data, ensuring compliance and maximizing rebate opportunities for healthcare providers. By facilitating rebates from drug manufacturers, Vitalyze helps hospitals and care centers reduce their pharmaceutical spending, enhancing their financial flexibility and ability to provide quality care.

Develops senoblockers, a novel class of therapeutics that target epigenetic regulators to reverse cellular senescence and restore stem cell activity. This approach addresses the decline in regenerative capacity and the accumulation of senescent cells, which are key contributors to age-related diseases.

PROSPERiA is a healthtech company focused on democratizing healthcare access through Artificial Intelligence solutions. The core platform automatically analyzes retina images to prevent blindness. This analysis provides personalized recommendations for both patients and medical professionals.

Thelium Therapeutics is developing therapeutic agents aimed at restoring intestinal barrier function in patients with inflammatory diseases. This approach targets the underlying dysfunction in the gut, which is critical for managing conditions such as inflammatory bowel disease.

Edge Animal Health develops novel therapeutics and vaccines for veterinary medicine by utilizing gene engineering tools and advanced cell therapies, addressing significant unmet healthcare needs in animals. The company applies biotechnological advancements from human health to improve disease prevention and treatment in pets and livestock.

Onward Assist is a predictive analytics platform that utilizes AI-driven image analysis to enhance cancer diagnosis by identifying biomarkers and reducing reporting time by 30-40%. The platform addresses the lack of effective cancer scoring tools tailored for diverse populations, enabling pathologists to make more accurate treatment decisions efficiently.

This platform connects customers with AI providers, streamlining the process of finding and engaging AI solutions. It simplifies access to diverse AI capabilities, enabling users to easily integrate AI into their workflows.

This company provides AI-powered tools specifically designed to enhance product discovery for online fashion retailers. Their platform offers features like intelligent fashion tagging, hybrid AI search, and personalized recommendations to improve shopper experience. The core value is increasing e-commerce conversion rates by deeply understanding fashion nuances in product catalogs.

The startup develops small molecule drugs that target nuclear receptors and master transcription factors to regulate cellular metabolism. This approach aims to enhance patient health by providing effective treatments for metabolic disorders.

SHS Health Tech utilizes artificial intelligence to connect healthcare institutions with suppliers of medical supplies and pharmaceuticals, optimizing procurement processes through data-driven insights. This approach reduces acquisition costs and enhances supply chain efficiency, addressing the challenges of fragmented purchasing and inconsistent supplier relationships in the healthcare sector.

Aptah Biosciences develops the RNA WiCo™ technology, an oligo-based approach that modulates U1-snRNP function to prevent premature transcription termination. This mechanism restores full-length RNA expression, correcting fundamental cellular mechanisms disrupted in various diseases. The technology aims to treat conditions like cancer, ophthalmology, autoimmune, and neurodegenerative disorders by ensuring proper gene expression fidelity.

VivaWell provides a digital health and wellness platform that uses AI and data science to deliver personalized health programs and quality healthcare. It helps individuals and organizations improve health outcomes and manage healthcare costs through tailored services and population health insights.

Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

Precision Data provides a business intelligence platform that utilizes generative artificial intelligence to optimize access to over 8 billion lines of structured clinical data, enhancing real-world evidence studies in healthcare. The company addresses the challenge of data quality and accessibility, enabling healthcare organizations to make informed decisions based on accurate and comprehensive information.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

AdvNanoT develops SirPlux™ Duo, a drug-coated balloon that utilizes biodegradable nanoparticles to deliver Sirolimus and Paclitaxel directly to arterial lesions, enhancing drug retention and cellular uptake. This technology addresses the challenges of atherosclerosis and blockage in coronary and peripheral artery diseases by providing stent-like patency without the complications associated with traditional stents.

Terraflos integrates the innovation cycle from discovering new active principles in plants to transforming them into evidence-based food, supplement, and dermocosmetic products optimized by AI. The company focuses on maximizing plant power through conscious science and technology across three key segments: supplements, food, and SkinTech. They utilize an Agentic AI called JEN to coordinate their network of B2B companies, ensuring alignment in purpose, vision, and execution for health and well-being solutions.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

Gennie is a generative AI platform that accelerates the product development process by over 10 times, utilizing advanced methodologies in Design Thinking and innovation processes. It addresses the lengthy time-to-market challenge by refining concepts early in the development cycle, enabling businesses to validate ideas more efficiently.

This biotechnology company develops novel health treatments utilizing genetically engineered viruses. Their platform focuses on repurposing viruses, such as the Zika virus, into therapeutic agents. The company is advancing a pipeline of biotherapeutics based on this specialized viral vector technology.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

CellRep develops an AI-powered platform to discover and validate compounds for non-genetic cell reprogramming. This approach optimizes cellular function to enhance therapeutic potential, addressing limitations in current cell therapies like CAR-T treatments. The company provides an end-to-end pipeline from target discovery through preclinical validation for applications in oncology and longevity.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

metaBIX develops advanced computational tools for accelerating drug discovery pipelines. The platform integrates machine learning models with high-throughput screening data to predict compound efficacy and toxicity profiles. This capability allows pharmaceutical researchers to rapidly identify viable therapeutic candidates with optimized physicochemical properties.

Phinomics provides a patented platform that isolates and decodes extrachromosomal circular DNA and cryptic micro-proteins, which are key drivers in cancer and immune dysfunction. This technology reveals previously invisible biology that conventional sequencing methods miss, offering a more complete view of disease mechanisms. By integrating these causal elements, the company aims to enable more accurate target discovery for next-generation therapeutics.

CuraSen Therapeutics develops orphan drugs targeting neurodegenerative diseases by utilizing advanced pharmacological approaches to enhance neuroprotection and promote neuronal health. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Alzheimer's and Parkinson's, where current treatment options are limited.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

MindImmune Therapeutics is developing a therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. This approach aims to address the underlying pathology of Alzheimer’s by preventing neuroinflammation and preserving cognitive function.